Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Daiichi Sankyo’s antibody–drug conjugate Datopotamab Deruxtecan secures U.S. approval, offering a new treatment for patients with previously treated …
Avance Clinical solidifies its position as the leading early‑phase CRO in Australia—backed by rapid trial starts and generous …
ViGeneron’s VG901 gains momentum with FDA rare pediatric disease status for CNGA1‑linked retinitis pigmentosa, while the EMA urges …
Bio‑Path outlines a robust development and regulatory path ahead, aiming to advance both cancer and obesity-focused therapies using …
A landmark U.S. FDA nod for Datopotamab deruxtecan (Datroway) marks a promising advance for treating metastatic HR‑positive, HER2‑negative …
Neumora Therapeutics sees its share value collapse as its lead antidepressant candidate, navacaprant, fails to outperform placebo in …
Caption By the end of 2024, emerging studies point to GLP‑1 receptor agonists—once mainly weight‑loss drugs—finding versatile application …
Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
A landmark regulatory update aims to speed approvals, reduce bureaucracy, and strengthen the UK’s position as a global …
Already a subscriber? Log in